Replidyne says FDA issues warning letter for faropenem

Jan 28 (Reuters) - Replidyne Inc RDYN.O said it received a warning letter from the U.S. Food and Drug Administration in regard to its antibiotic faropenem medoxomil 300 mg tablets twice per day dose.

In a filing with the U.S. Securities and Exchange Commission, the company said it intends to respond timely to the issues raised by the FDA. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Jarshad Kakkrakandy)